Abstract

A system for sorbent‐assisted peritoneal dialysis (SAPD) has been developed that continuously recirculates dialysate via a tidal mode using a single‐lumen peritoneal catheter with the regeneration of spent dialysate by means of sorbents. SAPD treatment may improve plasma clearance by the maintenance of a high plasma‐to‐dialysate concentration gradient and by increasing the mass transfer area coefficient (MTAC) of solutes. The system is designed for daily 8‐hr treatment (12 kg, nighttime system). A wearable system (2.3 kg, daytime system) may further enhance the clearance of phosphate and organic waste solutes during the day. Uremic pigs (n = 3) were treated with the day‐ (n = 3) and nighttime system (n = 15) for 4–8 hr per treatment. Plasma clearance (Cl), MTAC, and total mass transport (MT) of urea, creatinine, phosphate, and potassium were compared with a static dwell (n = 28). Cl, MTAC, and MT of urea, creatinine, phosphate, and potassium were low in the pig as compared to humans due to the pig's low peritoneal transport status and could be enhanced only to a limited extent by SAPD treatment compared with a static dwell (nighttime system: Cl urea: ×1.5 (p = .029), Cl creatinine: ×1.7 (p = .054), Cl phosphate: ×1.5 (p = .158), Cl potassium: ×1.6 (p = .011); daytime system: Cl creatinine: ×2.7 (p = .040), Cl phosphate: ×2.2 (p = .039)). Sorbent‐assisted peritoneal dialysis treatment in a uremic pig model is safe and enhances small solute clearance as compared to a static dwell. Future studies in humans or animal species with higher peritoneal transport should elucidate whether our SAPD system enhances clearance to a clinically relevant extent as compared to conventional PD.

Highlights

  • Peritoneal dialysis (PD) is a life-sustaining renal replacement therapy for patients with end-stage kidney disease (ESKD)

  • The vast majority (88%) of dialysis patients is treated with hemodialysis (HD) (Fresenius Medical Care, 2018), PD has several advantages compared with HD

  • Gentamicin (10 mg/kg 2dd for 7 days) was administered prior to the testing of the sorbent-assisted peritoneal dialysis (SAPD) system to induce acute-on-chronic kidney injury, resulting in plasma concentrations of uremic toxins in the range of those observed in dialysis patients

Read more

Summary

Funding information

This study was supported by the European Union (WEAKID, Horizon 2020 research and innovation program, grant agreement no. 733169) and by the Dutch Kidney Foundation and Dutch Ministry of Economic Affairs by means of a PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (DKF project code PPS08). Fondazione Cassa di Risparmio di Modena (grant IT Sime n.2016.0098) supported the work of G. Ligabue, S. Giovanella, and G. Cappelli.

| INTRODUCTION
| METHODS
| Experimental procedures
| RESULTS
Findings
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call